NanoSTING
NanoSTING platform is the first broad-acting intranasal host-directed-therapeutic that safely targets the STING pathway to boost the body’s innate immunity for the prevention and treatment of clinical respiratory disease as well as disruption of person-to-person transmission. Learn more by watching the following video.
AuraVax has two pipeline programs
The STING pathway is an evolutionarily conserved part of the body’s immune system that initiates our first response to infection from viral pathogens. NanoSTING platform has been specifically designed to engage this important defense in the upper airway where most respiratory infections initiate.
NanoSTING-001: The intranasal host-directed-therapeutic to offer broad treatment against respiratory pathogens
NanoSTING-002: The first safe effective mucosal adjuvant for human intranasal vaccines
AuraVax is developing NanoSTING-001 to address the unmet medical burden of respiratory viruses (such as influenza, SARS-CoV-2, RSV, and others) and emerging biothreats (such as Ebola, Mpox, and Hantavirus).
The breadth of these viral pathogens highlights the broad antiviral potential of NanoSTING-001. Early studies have shown its benefits as an early intervention or a complement to vaccination. Our plans for NanoSTING-001 are particularly focused on at-risk populations such as:
- Patients with comorbidities, such as diabetes, congestive heart failure, and other chronic diseases
- Poor responders to vaccination because of their age and/or immunosuppressed condition.
- Individuals at increased risk of exposure to a viral infection due to their occupation
Technology
Click here to read more about our new technology.
Publications
Check out our scientific works and publications.
Press Releases
Want to read about some of our latest press releases? Click here.
About Us
Meet the team of experts behind AuraVax.
Have questions?
Want to find out more about Auravax? Visit our contact page and send us a message.
NanoSTING Technology
Auravax’s proprietary formulation of nano particles to deliver an activator (agonist) of the STING (stimulator of interferon genes) pathway.
